CA2881121A1 - Improved daptomycin injectable formulation - Google Patents

Improved daptomycin injectable formulation Download PDF

Info

Publication number
CA2881121A1
CA2881121A1 CA2881121A CA2881121A CA2881121A1 CA 2881121 A1 CA2881121 A1 CA 2881121A1 CA 2881121 A CA2881121 A CA 2881121A CA 2881121 A CA2881121 A CA 2881121A CA 2881121 A1 CA2881121 A1 CA 2881121A1
Authority
CA
Canada
Prior art keywords
daptomycin
formulation
lyophilized
tpm
tocopheryl phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2881121A
Other languages
English (en)
French (fr)
Inventor
Satya Srinivas CHETLAPALLI
Srirama Sarveswara Rao MANDAVILLI
Babu JUSTIN
Sathyanarayan Srinivas MEDA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agila Specialities Pvt Ltd
Original Assignee
Agila Specialities Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agila Specialities Pvt Ltd filed Critical Agila Specialities Pvt Ltd
Publication of CA2881121A1 publication Critical patent/CA2881121A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2881121A 2012-08-23 2013-08-22 Improved daptomycin injectable formulation Abandoned CA2881121A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2452/MUM/2012 2012-08-23
IN2452MU2012 2012-08-23
PCT/IN2013/000511 WO2014045296A2 (en) 2012-08-23 2013-08-22 Improved daptomycin injectable formulation

Publications (1)

Publication Number Publication Date
CA2881121A1 true CA2881121A1 (en) 2014-03-27

Family

ID=54187094

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2881121A Abandoned CA2881121A1 (en) 2012-08-23 2013-08-22 Improved daptomycin injectable formulation

Country Status (12)

Country Link
US (1) US20150216928A1 (enExample)
EP (2) EP3287138A1 (enExample)
JP (1) JP2015526463A (enExample)
AU (2) AU2013319737B2 (enExample)
BR (1) BR112015003198A2 (enExample)
CA (1) CA2881121A1 (enExample)
DK (1) DK2887953T3 (enExample)
ES (1) ES2655215T3 (enExample)
NO (1) NO2887953T3 (enExample)
PT (1) PT2887953T (enExample)
SI (1) SI2887953T1 (enExample)
WO (1) WO2014045296A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE13837694T1 (de) 2012-09-11 2015-12-31 Hospira Australia Pty Ltd. Daptomycinformulierungen und Verwendungen davon
WO2018073269A1 (en) 2016-10-21 2018-04-26 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
MX2020001885A (es) 2017-08-31 2020-09-07 Xellia Pharmaceuticals Aps Formulaciones de daptomicina.
CA3170514A1 (en) 2020-03-12 2021-09-16 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
CN112684043A (zh) * 2020-12-16 2021-04-20 南京健友生化制药股份有限公司 一种达托霉素有关物质的检测方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
FR2657526B1 (fr) * 1990-01-31 1994-10-28 Lvmh Rech Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues.
WO1997014705A1 (fr) * 1995-10-17 1997-04-24 Showa Denko K.K. Phosphates de tocopherol tres purs, procedes de preparation, techniques d'analyse et produits cosmetiques correspondants
JP4088597B2 (ja) * 2004-01-06 2008-05-21 樹男 飯田 内服および注射用組成物とその製法
US20080032384A1 (en) * 2004-04-22 2008-02-07 Takehiko Nomura Pharmaceutical Preparation Containing Bacterial Cell Wall Skeleton
CA2611831C (en) * 2005-06-17 2014-09-16 Vital Health Sciences Pty Ltd. A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
CA2772660A1 (en) * 2009-09-01 2011-03-10 Northwestern University Delivery of therapeutic agents using oligonucleotide-modified nanoparticles as carriers
US8431539B2 (en) * 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
BR112012012406B1 (pt) * 2009-11-23 2021-11-16 Cubist Pharmaceuticals Llc Composições farmacêuticas sólidas de daptomicina, seu produto farmacêutico e seus métodos de fabricação
AU2011213557B2 (en) * 2010-02-05 2015-05-07 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CA2752784A1 (en) * 2010-09-21 2012-03-21 Xellia Pharmaceuticals Aps Daptomycin formulation

Also Published As

Publication number Publication date
BR112015003198A2 (pt) 2017-10-10
ES2655215T3 (es) 2018-02-19
DK2887953T3 (en) 2018-01-15
WO2014045296A2 (en) 2014-03-27
WO2014045296A3 (en) 2014-10-23
AU2018204334A1 (en) 2018-07-05
AU2013319737B2 (en) 2018-08-02
EP3287138A1 (en) 2018-02-28
PT2887953T (pt) 2018-01-10
JP2015526463A (ja) 2015-09-10
NO2887953T3 (enExample) 2018-03-10
EP2887953A4 (en) 2016-05-25
SI2887953T1 (en) 2018-02-28
EP2887953B1 (en) 2017-10-11
AU2013319737A1 (en) 2015-02-05
US20150216928A1 (en) 2015-08-06
EP2887953A2 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
AU2018204334A1 (en) Improved daptomycin injectable formulation
TWI606838B (zh) 達托黴素（ｄａｐｔｏｍｙｃｉｎ）組合物及相關方法
IL171337A (en) Pharmaceutical compositions containing piperacillin and tazobactam, uses thereof and processes for the preparation thereof
US20080103121A1 (en) Cephalosporin derivative formulation
CZ298581B6 (cs) Farmaceuticky stabilní prípravek oxaliplatiny k parenterální aplikaci
CN102462684A (zh) 头孢曲松钠和舒巴坦钠的药物组合物及其制备方法
WO2022129263A1 (en) Aqueous solution
KR101468153B1 (ko) 5α-안드로스테인-3β,5,6β-트리올 주사제 및 제조방법
RU2007152C1 (ru) Офтальмологическое средство и способ его получения
CN104352454A (zh) 注射用夫西地酸钠粉针剂药物组合物和制法
NO336427B1 (no) Farmasøytisk sammensetning av vinflunin som er ment for parenteral administrering, fremstillingsmåte og anvendelse derav
JP6063064B2 (ja) 安定したノカチアシン凍結乾燥製剤
CN102342931A (zh) 替莫唑胺的可注射的胃肠外用药物制剂及其制备方法
CN103330933B (zh) 含有米卡芬净或其盐的药物组合物
CN101554368B (zh) 一种室温稳定的注射用替曲朵辛组合物制剂
JP2020533318A (ja) ドセタキセル結合体の医薬組成物及び調製方法
CN101125125A (zh) 马来酸甲麦角新碱粉针剂及其制备方法
CN106176626B (zh) L-丙氨酸-(14-冬凌草甲素)酯胃肠外用药物组合物
JP3956654B2 (ja) Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物含有溶液および製剤
CN114469877A (zh) 一种司美格鲁肽植入剂及其制备方法
EP4110303A1 (en) Daptomycin formulation
JP7423028B2 (ja) ボルテゾミブを含有する凍結乾燥医薬組成物
CN103330932B (zh) 一种米卡芬净或其盐的药物组合物
RU2014050C1 (ru) Офтальмологическое средство и способ его получения
CN103735522A (zh) 一种炎琥宁冻干粉针及其制备方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180712

FZDE Discontinued

Effective date: 20200831

FZDE Discontinued

Effective date: 20200831